CellsBin Receives National Cancer Institute Award for Multiple Myeloma Blood Test Development
Biotechnology company CellsBin has been awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). The funding is designated to advance CB-Insight™, a proprietary technology designed to detect and recover living multiple myeloma cells directly from blood samples. This approach aims to provide clinicians with bone marrow-level biological insights through routine blood draws, reducing the need for invasive bone marrow biopsies. The program will transition from early proof-of-concept into formal clinical testing in patients, led by investigators from the Yale School of Medicine. By combining microfluidics, high-resolution imaging, and machine learning, CellsBin intends to capture intact cells for deep genetic and molecular analysis. This development follows a recent Series A financing round led by 108 BioCapital.
Topics: Biotechnology funding Blood-based testing Multiple Myeloma National Cancer Institute SBIR Award